

Research Article

Elevated hsCRP levels signal increased risk of future cardiovascular disease independent of lipid profile in *H. pylori* infection

Gaurav Shashikant Kansara^{1*}, Pooja Nitin Joshi², Shyam Rameshwar Adhau³

¹Department of Biochemistry, L. T. Medical College, Sion (west), Mumbai, Maharashtra, India

²Department of Biochemistry, B. J. Govt. Medical College, Pune, Maharashtra, India

³Department of Biochemistry, S. B. H. Govt. Medical College, Dhule, Maharashtra, India

Received: 30 July 2014

Accepted: 10 August 2014

*Correspondence:

Dr. Gaurav Shashikant Kansara,

E-mail: Kansara_gaurav@yahoo.co.in

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: There are reports that *Helicobacter pylori* (*H. pylori*) infection leads to changes in serum lipid profile and high sensitivity C-reactive protein (hsCRP) levels, but role of *H. pylori* in causing increased risk of cardiovascular disease remains a topic of debate.

Methods: A case control study was conducted, in subjects without pre-existing atherosclerotic disease. We studied 72 otherwise healthy subjects in the age group of 20 to 60 years. All subjects underwent gastroduodenoscopy and *H. pylori* infection status was assessed by rapid urease test.

Results: There were no statistical differences in serum total cholesterol, triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol levels or total cholesterol/HDL cholesterol ratios between cases and controls. However, serum hsCRP (high sensitivity C-reactive protein) levels were significantly higher in cases as compared to controls ($P < 0.05$).

Conclusion: The results of this study showed that *H. pylori* infection does not modify serum lipid levels; however, it leads to a rise in hsCRP, an important risk factor for atherosclerosis. It can be concluded that *H. pylori* infection may contribute to atherogenesis through the state of chronic inflammation, which is evidenced by elevated hsCRP levels.

Keywords: *Helicobacter pylori*, Cholesterol, HDL cholesterol, LDL cholesterol, Triglyceride, C-reactive protein

INTRODUCTION

Infection with *Helicobacter pylori* (*H. pylori*), a gram negative bacterium, is the most widespread infection in the world. Prevalence in India is more than 80% in population above 20 years of age.¹ Colonization of gastric mucosa with *H. pylori* is known to be associated with upper gastrointestinal disorders, including gastric carcinoma and gastric cancer.

Altered levels of serum Total Cholesterol (TC), Low Density Lipoprotein cholesterol (LDL-c), triglycerides (TG), High Density Lipoprotein cholesterol (HDL-c) and

high sensitivity C-reactive protein (hsCRP) are known risk factors for cardiovascular disease, stroke and metabolic syndrome.² hsCRP measurement is now accepted as useful for risk assessment of future cardiovascular events.³

Some studies suggest that *H. pylori* infection leads to elevated levels of serum TC, LDL-c, TG and hsCRP and decreased levels of HDL-c.⁴⁻²² This is refuted by other studies.²³⁻³⁰

The effect of *H. pylori* infection on serum lipid profile and hsCRP levels remains a matter of debate. Many of

these studies were carried out on western populations, in subjects with pre-existing coronary artery disease.

The purpose of this study was to investigate the influence of *H. pylori* infection on cardiovascular risk factors (lipid profile and hsCRP levels) in relatively younger Indian subjects without pre-existing atherosclerotic disease. This would presumably help in devising strategies for prevention of future atherosclerotic events in this group.

METHODS

Study subjects

Our study consisted of both male and female subjects attending the gastroduodenoscopy clinics of the departments of internal medicine and surgery at B. J. govt. medical college, Pune. Many subjects were excluded according to the following criteria: 1) Patients below 20 years and above 60 years. of age, 2) Hypertensive or diabetic patients, 3) Patients with altered kidney and liver function indices, 4) Smokers and alcoholics, 5) Patients with previous history of ischaemic heart disease or thyroid disorders, 6) Patients on drug therapy known to alter lipid indices (e.g. β -blockers, OC pills), and 7) Patients receiving antihyperlipidemic therapy. Finally, a total of 72 subjects, both male and female, were included in the present study. 36 *H. pylori* infected cases and an equal number of age and sex matched controls without *H. pylori* infection were to be selected.

Data collection

Information regarding underlying diseases, medication history and addiction to alcohol or smoking was recorded using a standardised questionnaire.

Hypertension and diabetes were ruled out by searching for physician reports, lab findings or use of antihypertensive or antidiabetic medications. 5 ml of venous blood was obtained from each participant after an overnight fast (≥ 12 hours).

Total cholesterol, HDL cholesterol and triglycerides were measured by enzymatic methods using an automated chemistry analyzer (ERBA XL 640).³¹⁻³⁴ LDL cholesterol was calculated using the Friedewald equation.³⁵ Total cholesterol by HDL cholesterol ratio was calculated from the above values. hsCRP levels were estimated by an immunoturbidimetric method on a semiautomated analyser (ERBA Chem 5 plus). In this method, latex particles coated with specific anti-human CRP are agglutinated when mixed with samples containing CRP. The agglutination causes an absorbance change, dependent upon the CRP content of the patient sample. Values less than 0.05 mg/L gave non-reproducible results with this method. Undetectable CRP values were recorded as 0.025 mg/L.¹¹

Rapid urease test

All study subjects underwent a rapid urease test in the endoscopy room. The method used for rapid urease test for the detection of pre-formed urease enzyme was as per described by Arvind et al.^{36,37}

One biopsy sample was introduced in the rapid urease test solution in the endoscopy room. Development of a dark pink colour from the initial pale yellow was checked at 1 min, 5 min, ½ hour, 1 hour and 3 hours. If during these 3 hours the colour changed to pink, then rapid urease test was recorded as being positive for *H. pylori* infection.

Statistics

Data are presented as mean values with standard deviations. The continuous variables were compared using the Student's unpaired t-test. All the calculations were done using Microsoft Office excel 2007. A two tailed P-value of less than 0.05 ($P < 0.05$) was considered to be statistically significant.

The study protocol was approved by the institutional ethics committee of B. J. Govt. medical college, Pune.

RESULTS

Among the 72 subjects, 36 subjects were positive and 36 were negative for *H. pylori* infection by rapid urease test. There were no significant differences in lipid profile or total cholesterol by HDL cholesterol ratio between the 2 groups ($P > 0.05$). However, hsCRP levels were significantly elevated in *H. pylori* infected as compared to non-infected group (Table 1).

Table 1: Characteristics of study participants.

Characteristics	<i>H. pylori</i> non-infected group (n=36)	<i>H. pylori</i> infected group (n=36)
Age (years)	37.97 \pm 11.21	38.94 \pm 10.91
Male sex (%)	66.7	66.7
Chronic alcoholic/smoker	None	None
Total cholesterol (mg/dl)	175.1 \pm 36.4	170.5 \pm 36.6
Triglycerides (mg/dl)	132.9 \pm 39.0	128 \pm 42.9
HDL-cholesterol (mg/dl)	42.14 \pm 3.65	40.77 \pm 4.72
LDL-cholesterol (mg/dl)	106.3 \pm 34.5	104.2 \pm 31.9
Total cholesterol/HDL ratio	4.18 \pm 0.9	4.21 \pm 0.88
hsCRP (mg/L)*	0.17 \pm 5.07	0.43 \pm 4.54 [†]

Values are expressed as mean \pm standard deviation. *geometric mean, [†] $P < 0.05$

H. pylori, *Helicobacter pylori*; HDL, high density lipoprotein; LDL, low density lipoprotein; hsCRP, high sensitivity C-reactive protein

DISCUSSION

H. pylori infection leads to chronic inflammation of the gastric mucosa. This leads to systemic release of inflammatory cytokines, one of the contributory factors of atherosclerosis. Alteration in lipid profile is another consequence of this systemic inflammatory state. Hence, *H. pylori* infection may lead to increase in risk of coronary artery disease. It is well documented that a rise in inflammatory cytokine-interleukin 6 is primarily responsible for a rise in hsCRP production by the liver.³⁸ Our study also shows a statistically significant increase in hsCRP levels in *H. pylori* infection. ($P = 0.01$) Raised hsCRP levels have been shown to be associated with higher risk of cardiovascular events.

It is observed that *H. pylori* infection is not associated with changes in lipid profile in our study population, which consists of young Indians. In contrast to various studies which postulate a change in lipid profile in *H. pylori* infection,^{4,22} the present study shows that levels of TC, LDL and TG are reduced in *H. pylori* infection, even though the decrease is not statistically significant. Levels of HDL cholesterol are also reduced in *H. pylori* infection, even though this did not reach statistical significance. ($P = 0.17$) The TC/HDL ratio was found to be weakly higher in cases as compared to controls.

It was shown that subjects with raised levels of hsCRP but low levels of LDL cholesterol are at a greater risk of future cardiovascular events than subjects with low levels of hsCRP but raised levels of LDL cholesterol.³⁹ This shows that *H. pylori* infection may lead to a significant increase in the risk for future cardiovascular disease, independent of any effect on serum lipid levels.

In one study, strains of *H. pylori* carrying the cytotoxin associated gene A (cag A) have been found to be more pathogenic in terms of raising serum lipid levels as compared to strains lacking it,²¹ while another study refutes this.⁸ One limitation of our work is that the cag A status of the bacterium was not taken into account in our study; this needs to be assessed in future studies.

As a conclusion, the results of this study suggest that *H. pylori* infection is associated with elevated hsCRP levels, an important risk factor for atherosclerosis, independent of lipid profile. Eradication of *H. pylori* may help in preventing atherosclerosis by eliminating the cause of systemic inflammation, which is responsible for the cytokine release leading to an atherogenic state.

ACKNOWLEDGEMENTS

The authors gratefully acknowledge the help received from the departments of internal medicine and surgery of B. J. medical college, Pune, for collection of clinical data, and help from the department of preventive and social medicine as regards sample size calculation and statistical analysis.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: The study was approved by the institutional ethics committee of B. J. govt. medical college, Pune and with the Helsinki declaration of 1975 that was revised in 2000

REFERENCES

- Graham DY, Adam E, Reddy GT, Agarwal JP, Agarwal R, Evans DJ Jr, et al. Seroepidemiology of *Helicobacter pylori* infection in India. Comparison of developing and developed countries. *Dig Dis Sci.* 1991 Aug;36(8):1084-8.
- Mancini GB, Dahlöf B, Díez J. Surrogate markers for cardiovascular disease: structural markers. *Circulation.* 2004 Jun;109(25 Suppl 1):IV22-30.
- Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med.* 2002 Nov;347(20):1557-65.
- Strachan DP, Mendall MA, Carrington D, Butland BK, Yarnell JW, Sweetnam PM, et al. Relation of *Helicobacter pylori* infection to 13-year mortality and incident ischemic heart disease in the Caerphilly prospective heart disease study. *Circulation.* 1998 Sep;98(13):1286-90.
- Zuberi BF, Shaikh SA, Shaikh WM, Shaikh GM, Jatoti N. IgG antibodies against *H. pylori* in patients of myocardial infarction. *J Coll Physicians Surg Pak.* 1998;8(6):249-51.
- Laurila A, Bloigu A, Nayha S, Hassi J, Leinonen M, Saikku P. Association of *Helicobacter pylori* infection with elevated serum lipids. *Atherosclerosis.* 1999;142:207-10.
- Hoffmeister A, Rothenbacher D, Bode G, Persson K, März W, Nauck MA, et al. Current infection with *Helicobacter pylori*, but not seropositivity to *Chlamydia pneumoniae* or cytomegalovirus, is associated with an atherogenic, modified lipid profile. *Arterioscler Thromb Vasc Biol.* 2001 Mar;21(3):427-32.
- Chimienti G, Russo F, Lamanuzzi BL, Nardulli M, Messa C, Di Leo A, et al. *Helicobacter pylori* is associated with modified lipid profile: impact on lipoprotein(a). *Clin Biochem.* 2003 Jul;36(5):359-65.
- Kanbay M, Gür G, Yücel M, Yılmaz U, Boyacıoğlu S. Does eradication of *Helicobacter pylori* infection help normalize serum lipid and CRP levels? *Dig Dis Sci.* 2005 Jul;50(7):1228-31.
- Longo-Mbenza B, Nkondi Nsenga J, Vangu Ngoma D. Prevention of the metabolic syndrome insulin resistance and the atherosclerotic diseases in Africans infected by *Helicobacter pylori* infection and treated by antibiotics. *Int J Cardiol.* 2007 Oct;121(3):229-38.
- Ishida Y, Suzuki K, Taki K, Niwa T, Kurotsuchi S, Ando H, et al. Significant association between

- Helicobacter pylori infection and serum C-reactive protein. *Int J Med Sci.* 2008 Jul;5(4):224-9.
12. Ugwuja EI, Ugwu NC. Plasma lipids in Helicobacter pylori infected pregnant women. *Int J Med Med Sci.* 2009 May;1(5):224-6.
 13. Jia EZ, Zhao FJ, Hao B, Zhu TB, Wang LS, Chen B, et al. Helicobacter pylori infection is associated with decreased serum levels of high density lipoprotein, but not with the severity of coronary atherosclerosis. *Lipids Health Dis.* 2009 Dec;23(8):59.
 14. Ansari MHK, Omrani M, Sayyah B, Ansari SK. Effect of Helicobacter pylori infection on the lipid, lipoproteins, apolipoprotein-A1, lipoprotein (a) and apolipoprotein-B in patients with gastritis. *Afr J Microbiol Res.* 2010 Jan;4(1):84-7.
 15. Gen R, Demir M, Ataseven H. Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation. *South Med J.* 2010 Mar;103(3):190-6.
 16. Kebapcilar L, Bilgir O, Cetinkaya E, Akyol M, Bilgir F, Bozkaya G. The effect of Helicobacter pylori eradication on macrophage migration inhibitory factor, C-reactive protein and fetuin-a levels. *Clinics (Sao Paulo).* 2010 Jun;65(8):799-802.
 17. Akbas HS, Basyigit S, Suleymanlar I, Kemaloglu D, Koc S, Davran F, et al. The assessment of carotid intima media thickness and serum paraoxonase-1 activity in Helicobacter pylori positive subjects. *Lipids Health Dis.* 2010 Aug;9:92.
 18. Jalalzadeh M, Saber HR, Vafaieimanesh J, Mirzamohammadi F, Falaknazi K. Association of Helicobacter pylori infection and serum albumin in patients on hemodialysis. *Iran J Kidney Dis.* 2010 Oct;4(4):312-6.
 19. Satoh H, Saijo Y, Yoshioka E, Tsutsui H. Helicobacter pylori infection is a significant risk for modified lipid profile in Japanese male subjects. *J Atheroscler Thromb.* 2010 Oct;17(10):1041-8.
 20. Aarabi MH, Alvani S, Ehteram H. Lipid Profile in Subjects with Helicobacter pylori infection. *Iranian J Pathol.* 2010;5(4):199-203.
 21. Huang B, Chen Y, Xie Q, Lin G, Wu Y, Feng Y, et al. CagA-positive Helicobacter pylori strains enhanced coronary atherosclerosis by increasing serum oxLDL and hsCRP in patients with coronary heart disease. *Dig Dis Sci.* 2011 Jan;56(1):109-14.
 22. Hack-Lyong Kim, Han Ho Jeon, In Young Park, Jin Man Choi, Ji Sun Kang, Kyueng-Whan Min. Helicobacter pylori infection is associated with elevated low density lipoprotein cholesterol levels in elderly Koreans. *J Korean Med Sci.* 2011;26:654-8.
 23. Murray LJ, Bamford KB, O'Reilly DP, McCrum EE, Evans AE. Helicobacter pylori infection: relation with cardiovascular risk factors, ischaemic heart disease, and social class. *Br Heart J.* 1995 Nov;74(5):497-501.
 24. Regnström J, Jovinge S, Båvenholm P, Ericsson C-G, De Faire U, Hamsten A, et al. Helicobacter pylori seropositivity is not associated with inflammatory parameters, lipid concentrations and coronary artery disease. *J Intern Med.* 1998 Feb;243:109-13.
 25. Pilotto A, Rumor F, Franceschi M, Leandro G, Novello R, Soffiati G, et al. Lack of association between Helicobacter pylori infection and extracardiac atherosclerosis in dyspeptic elderly subjects. *Age Ageing.* 1999 Jul;28(4):367-71.
 26. Kowalski M. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty: the detection of H. pylori specific DNA in human coronary atherosclerotic plaque. *J Physiol Pharmacol.* 2001 Aug;52(1 Suppl 1):3-31.
 27. Elizalde JI, Piqué JM, Moreno V, Morillas JD, Elizalde I, Bujanda L, et al. Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. *Aliment Pharmacol Ther.* 2002 Mar;16(3):577-86.
 28. Ongey M, Brenner H, Thefeld W, Rothenbacher D. Helicobacter pylori and hepatitis A virus infections and the cardiovascular risk profile in patients with diabetes mellitus: results of a population-based study. *Eur J Cardiovasc Prev Rehabil.* 2004 Dec;11(6):471-6.
 29. Volanen I, Raitakari OT, Vainionpää R, Arffman M, Aarnisalo J, Anglé S, et al. Serum lipid profiles poorly correlate with Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus seropositivity in prospectively followed-up healthy children. *Arterioscler Thromb Vasc Biol.* 2005 Apr;25(4):827-32.
 30. Zhang L, Gail MH, Wang YQ, Brown LM, Pan KF, Ma JL, et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. *Am J Clin Nutr.* 2006 Oct;84(4):912-9.
 31. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. *Clin Chem.* 1974;20:470-5.
 32. Roeschlau P, Bernt E, Gruber WA. Enzymatic analysis of total cholesterol. *Clin Chem Clin Biochem.* 1974;12:226-8.
 33. Burstein M, Scholinick HR, Marfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. *J Lipid Res.* 1970;11:583-95.
 34. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. *Clin Chem.* 1982;28:2077-80.
 35. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem.* 1972;18:499-502.

36. Arvind AS, Cook RS, Tabaqchali S, Farthing MJG. One minute endoscopy room test for *Campylobacter pylori*. *Lancet.* 1988;i:704.
37. Thillainayagam AV, Arvind AS, Cook RS, Harrison IG, Tabaqchali S, Farthing MJG. Diagnostic efficiency of an ultrarapid endoscopy room test for *Helicobacter pylori*. *Gut.* 1991;32:467-9.
38. Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. *Eur Heart J.* 2000;21:1574-83.
39. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med.* 2002 Nov;347(20):1557-65.

DOI: 10.5455/2320-6012.ijrms20141127

Cite this article as: Kansara GS, Joshi PN, Adhau SR. Elevated hsCRP levels signal increased risk of future cardiovascular disease independent of lipid profile in *H. pylori* infection. *Int J Res Med Sci* 2014;2:1388-92.